Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
ACADIA Pharmaceuticals
ACAD
ACADIA Pharmaceuticals
Government Scrutiny And Patent Risks Will Erode Long Term Value
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
06 May 25
Updated
23 Jul 25
4
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$16.24
50.2% overvalued
intrinsic discount
23 Jul
US$24.40
Loading
1Y
55.3%
7D
2.4%
Author's Valuation
US$16.2
50.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$16.2
50.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-306m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.2b
Earnings US$31.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.93%
Biotech revenue growth rate
11.84%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$31.08m
Earnings '28
x
107.66x
PE Ratio '28
=
US$3.35b
Market Cap '28
US$3.35b
Market Cap '28
/
171.90m
No. shares '28
=
US$19.46
Share Price '28
US$19.46
Share Price '28
Discounted to 2025 @ 6.40% p.a.
=
US$16.16
Fair Value '25